Compare Citius Pharmaceuticals Inc (CTXR) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs TORM plc — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while TORM plc trades at $29.7 (market cap $3.02B). The key difference: TORM plc is far larger — about 206.3× Citius Pharmaceuticals Inc's market cap, and TORM plc pays a 9.52% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | TRMD | |
|---|---|---|
Market Cap | $14.64M | $3.02B |
Sector | Health | Technology |
52-Week High | $1.82 | $34.87 |
52-Week Low | $0.53 | $17.46 |
Enterprise Value | $10.86M | $3.90B |
Dividend Yield | — | 9.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
TRMD trades at $28.86, down 2.1% today, with a bullish technical signal supported by moving averages despite neutral oscillators. The company shows strong fundamentals with a P/E of 8.62, net income margin of 24.41%, and robust cash flow generation. Recent Q1 2026 earnings missed expectations but management raised full-year guidance, highlighting strong freight market conditions and operational execution.
Outlook remains positive with 100% analyst buy ratings and attractive valuation metrics. Key opportunities include the upcoming Q2 2026 earnings report and consistent dividend payments. Risks include earnings volatility, geopolitical impacts on shipping rates, and competitive pressures in the tanker market that could affect future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
